fMRI Biomarker of Early Neuronal Dysfunction in Presymptomatic Huntington’s Disease

References

1. ↵
   The Huntington’s Disease Collaborative Research Group: a novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993;72:971–983

   CrossRefPubMedWeb of ScienceGoogle Scholar
2. ↵
   Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 1985;44:559–577

   CrossRefPubMedWeb of ScienceGoogle Scholar
3. ↵
   Myers RH, Vonsattel JP, Stevens TJ, et al. Clinical and neuropathologic assessment of severity in Huntington’s disease. Neurology 1988;38:341–347

   Abstract/FREE Full TextGoogle Scholar
4. ↵
   Wagster MV, Hedreen JC, Peyser CE, Folstein SE, Ross CA. Selective loss of [3H]kainic acid and [3H]AMPA binding in layer VI of frontal cortex in Huntington’s disease. Exp Neurol 1994;127:70–75

   CrossRefPubMedWeb of ScienceGoogle Scholar
5. Sotrel A, Paskevich PA, Kiely DK, Bird ED, Williams RS, Myers RH. Morphometric analysis of the prefrontal cortex in Huntington’s disease. Neurology 1991;41:1117–1123

   Abstract/FREE Full TextGoogle Scholar
6. ↵
   Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington’s disease. Neurosci Lett 1991;133:257–261

   CrossRefPubMedWeb of ScienceGoogle Scholar
7. ↵
   Campodonico JR, Aylward E, Codori AM, et al. When does Huntington’s disease begin? J Intl Neuropsychol Soc 1998;4:467–473

   CrossRefGoogle Scholar
8. ↵
   Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease. Mov Disord 2000;15:552–560

   CrossRefPubMedWeb of ScienceGoogle Scholar
9. Harris GJ, Codori AM, Lewis RF, Schmidt E, Bedi A, Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington’s disease. Brain 1999;122:1667–1678

   Abstract/FREE Full TextGoogle Scholar
10. ↵
    Paulsen JS, Zhao H, Stout JC, et al. Clinical markers of early disease in persons near onset of Huntington’s disease. Neurology 2001;57:658–662

    Abstract/FREE Full TextGoogle Scholar
11. ↵
    Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797–801

    CrossRefPubMedWeb of ScienceGoogle Scholar
12. ↵
    Dedeoglu A, Kubilus JK, Yang L, et al. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington’s disease transgenic mice. J Neurochem 2003;85:1359–1367

    CrossRefPubMedWeb of ScienceGoogle Scholar
13. ↵
    Maricq AV, Church RM. The differential effects of haloperidol and methamphetamine on time estimation in the rat. Psychopharmacology (Berl) 1983;79:10–15

    CrossRefPubMedGoogle Scholar
14. ↵
    Rammsayer TH. Neuropharmacological evidence for different timing mechanisms in humans. Q J Exp Psychol B 1999;52:273–286

    CrossRefPubMedWeb of ScienceGoogle Scholar
15. ↵
    Artieda J, Pastor MA, Lacruz F, Obeso JA. Temporal discrimination is abnormal in Parkinson’s disease. Brain 1992;115:199–210

    Abstract/FREE Full TextGoogle Scholar
16. ↵
    O’Boyle DJ, Freeman JS, Cody FW. The accuracy and precision of timing of self-paced, repetitive movements in subjects with Parkinson’s disease. Brain 1996;119:51–70

    Abstract/FREE Full TextGoogle Scholar
17. ↵
    Rao SM, Mayer AR, Harrington DL. The evolution of brain activation during temporal processing. Nat Neurosci 2001;4:317–323

    CrossRefPubMedWeb of ScienceGoogle Scholar
18. ↵
    Woodruff-Pak DS, Papka M. Huntington’s disease and eyeblink classical conditioning: normal learning but abnormal timing. J Intl Neuropsychol Soc 1996;2:323–334

    Google Scholar
19. ↵
    Langbehn DR, Brinkmann RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of age of onset and penetrance for Huntington’s Disease based on CAG length. Clin Genet 2004;65:267–277

    CrossRefPubMedWeb of ScienceGoogle Scholar
20. ↵
    Oldfield RC. The assessment and analysis of handedness: the Edinburgh Inventory. Neuropsychologia 1971;9:97–113

    CrossRefPubMedWeb of ScienceGoogle Scholar
21. ↵
    Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997;60:1202–1210

    CrossRefPubMedWeb of ScienceGoogle Scholar
22. ↵
    Huntington Study Group. Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136–142

    CrossRefPubMedWeb of ScienceGoogle Scholar
23. ↵
    Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996;29:162–173

    CrossRefPubMedWeb of ScienceGoogle Scholar
24. ↵
    Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. New York: Thieme,1988

    Google Scholar
25. ↵
    Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 2000;10:120–131

    CrossRefPubMedWeb of ScienceGoogle Scholar
26. ↵
    Weeks RA, Ceballos-Baumann A, Piccini P, Boecker H, Harding AE, Brooks DJ. Cortical control of movement in Huntington’s disease: a PET activation study. Brain 1997;120:1569–1578

    Abstract/FREE Full TextGoogle Scholar
27. ↵
    Bartenstein P, Weindl A, Spiegel S, et al. Central motor processing in Huntington’s disease: a PET study. Brain 1997;120:1553–1567

    Abstract/FREE Full TextGoogle Scholar
28. ↵
    Haslinger B, Erhard P, Kampfe N, et al. Event-related functional magnetic resonance imaging in Parkinson’s disease before and after levodopa. Brain 2001;124:558–570

    Abstract/FREE Full TextGoogle Scholar
29. ↵
    Tobin AJ, Signer ER. Huntington’s disease: the challenge for cell biologists. Trends Cell Biol 2000;10:531–536

    CrossRefPubMedWeb of ScienceGoogle Scholar
30. ↵
    Cepeda C, Ariano MA, Calvert CR, et al. NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 2001;66:525–539

    CrossRefPubMedWeb of ScienceGoogle Scholar
31. ↵
    Cherry JA, Thompson BE, Pho V. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse. Biochim Biophys Acta 2001;1518:27–35

    PubMedGoogle Scholar
32. ↵
    Foroud T, Siemers E, Kleindorfer D, et al. Cognitive scores in carriers of Huntington’s disease gene compared to noncarriers. Ann Neurol 1995;37:657–664

    CrossRefPubMedWeb of ScienceGoogle Scholar
33. ↵
    Lawrence AD, Hodges JR, Rosser AE, et al. Evidence for specific cognitive deficits in preclinical Huntington’s disease. Brain 1998;121:1329–1341

    Abstract/FREE Full TextGoogle Scholar
34. ↵
    Albin RL, Reiner A, Anderson KD, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington’s disease. Ann Neurol 1992;31:425–430

    CrossRefPubMedWeb of ScienceGoogle Scholar
35. Albin RL, Young AB, Penney JB, et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington’s disease. N Engl J Med 1990;322:1293–1298

    CrossRefPubMedWeb of ScienceGoogle Scholar
36. ↵
    Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ. Reduced basal ganglia volume associated with the gene for Huntington’s disease in asymptomatic at-risk persons. Neurology 1994;44:823–828

    Abstract/FREE Full TextGoogle Scholar
37. ↵
    Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996;53:1293–1296

    CrossRefPubMedWeb of ScienceGoogle Scholar
38. ↵
    Harris GJ, Pearlson GD, Peyser CE, et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington’s disease. Ann Neurol 1992;31:69–75

    CrossRefPubMedWeb of ScienceGoogle Scholar
39. ↵
    Starkstein SE, Brandt J, Bylsma F, Peyser C, Folstein M, Folstein SE. Neuropsychological correlates of brain atrophy in Huntington’s disease: a magnetic resonance imaging study. Neuroradiology 1992;34:487–489

    CrossRefPubMedWeb of ScienceGoogle Scholar
40. ↵
    Campodonico JR, Codori AM, Brandt J. Neuropsychological stability over two years in asymptomatic carriers of the Huntington’s disease mutation. J Neurol Neurosurg Psychiatry 1996;61:621–624

    Abstract/FREE Full TextGoogle Scholar
41. ↵
    Riesen JM, Schnider A. Time estimation in Parkinson’s disease: normal long duration estimation despite impaired short duration discrimination. J Neurol 2001;248:27–35

    CrossRefPubMedWeb of ScienceGoogle Scholar
42. ↵
    Harrington DL, Haaland KY, Hermanowicz N. Temporal processing in the basal ganglia. Neuropsychology 1998;12:3–12

    CrossRefPubMedWeb of ScienceGoogle Scholar